6FX0

Structure-based design of Trifarotene (CD5789), a potent and selective RAR gamma agonist for the treatment of acne

Summary for 6FX0

Entry DOI	10.2210/pdb6fx0/pdb
Descriptor	Retinoic acid receptor gamma, 6-[3-(1-adamantyl)-4-oxidanyl-phenyl]naphthalene-2-carboxylic acid, TETRAETHYLENE GLYCOL, ... (4 entities in total)
Functional Keywords	retinoic ligand complex, drug design, selectivity, agonist, signaling protein
Biological source	Homo sapiens (Human)
Cellular location	Nucleus: P13631
Total number of polymer chains	1
Total formula weight	50997.57
Authors	Chantalat, L.,Thoreau, E. (deposition date: 2018-03-08, release date: 2018-05-23)
Primary citation	Thoreau, E.,Arlabosse, J.M.,Bouix-Peter, C.,Chambon, S.,Chantalat, L.,Daver, S.,Dumais, L.,Duvert, G.,Feret, A.,Ouvry, G.,Pascau, J.,Raffin, C.,Rodeville, N.,Soulet, C.,Tabet, S.,Talano, S.,Portal, T. Structure-based design of Trifarotene (CD5789), a potent and selective RAR gamma agonist for the treatment of acne. Bioorg. Med. Chem. Lett., 28:1736-1741, 2018 Cited by PubMed: 29706423 DOI: 10.1016/j.bmcl.2018.04.036 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.9 Å)

Structure validation